Polypharmacology: drug discovery for the future

In recent years, even with remarkable scientific advancements and a significant increase of global research and development spending, drugs are frequently withdrawn from markets. This is primarily due to their side effects or toxicities. Drug molecules often interact with multiple targets, coined as polypharmacology, and the unintended drug–target interactions could cause side effects. Polypharmacology remains one of the major challenges in drug development, and it opens novel avenues to rationally design the next generation of more effective, but less toxic, therapeutic agents. This review outlines the latest progress and challenges in polypharmacology studies.

[1]  Evan Bolton,et al.  PubChem's BioAssay Database , 2011, Nucleic Acids Res..

[2]  Fu Wei,et al.  Evaluation of various inverse docking schemes in multiple targets identification. , 2010, Journal of molecular graphics & modelling.

[3]  A. Barabasi,et al.  Drug—target network , 2007, Nature Biotechnology.

[4]  Ravi Iyengar,et al.  Systems pharmacology. , 2010, The Mount Sinai journal of medicine, New York.

[5]  A. Hopkins.  Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[6]  Jonathan D. Wren,et al.  Knowledge discovery by automated identification and ranking of implicit relationships , 2004, Bioinform..

[7]  H. Topka,et al.  Aspirin non-responder status in patients with recurrent cerebral ischemic attacks , 2003, Journal of Neurology.

[8]  K. Bretonnel Cohen,et al.  Text mining and manual curation of chemical-gene-disease networks for the Comparative Toxicogenomics Database (CTD) , 2009, BMC Bioinformatics.

[9]  A. Hopkins,et al.  Navigating chemical space for biology and medicine , 2004, Nature.

[10]  David S. Wishart,et al.  DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..

[11]  Joanna L. Sharman,et al.  IUPHAR-DB: An Expert-Curated, Peer-Reviewed Database of Receptors and Ion Channels , 2009 .

[12]  M. Dickson,et al.  Key factors in the rising cost of new drug discovery and development , 2004, Nature Reviews Drug Discovery.

[13]  Kevan M. Shokat,et al.  Chemical genetic discovery of targets and anti-targets for cancer polypharmacology , 2012, Nature.

[14]  J. Jassem,et al.  The role of pemetrexed combined with targeted agents for non-small cell lung cancer. , 2010, Current drug targets.

[15]  Yanli Wang,et al.  Structure-Based Virtual Screening for Drug Discovery: a Problem-Centric Review , 2012, The AAPS Journal.

[16]  A. Barabasi,et al.  Functional and topological characterization of protein interaction networks , 2004, Proteomics.

[17]  Tudor I. Oprea,et al.  Associating Drugs, Targets and Clinical Outcomes into an Integrated Network Affords a New Platform for Computer‐Aided Drug Repurposing , 2011, Molecular informatics.

[18]  J. Brahmer,et al.  Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer , 2011, Cancer investigation.

[19]  Thomas C. Wiegers,et al.  The Comparative Toxicogenomics Database facilitates identification and understanding of chemical-gene-disease associations: arsenic as a case study , 2008, BMC Medical Genomics.

[20]  Ferenc Csizmadia.  JChem: Java Applets and Modules Supporting Chemical Database Handling from Web Browsers , 2000, J. Chem. Inf. Comput. Sci..

[21]  Anders Wallqvist,et al.  Exploring Polypharmacology Using a ROCS-Based Target Fishing Approach , 2012, J. Chem. Inf. Model..

[22]  Michael J. Keiser,et al.  Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets , 2012, Nature.

[23]  Andrew L. Hopkins,et al.  Drug discovery: Predicting promiscuity , 2009, Nature.

[24]  Allard Kaptein,et al.  Irreversible protein kinase inhibitors: balancing the benefits and risks. , 2012, Journal of medicinal chemistry.

[25]  Yoshihiro Yamanishi,et al.  Prediction of drug–target interaction networks from the integration of chemical and genomic spaces , 2008, ISMB.

[26]  Y.Z. Chen,et al.  Ligand–protein inverse docking and its potential use in the computer search of protein targets of a small molecule , 2001, Proteins.

[27]  J. Lisziewicz,et al.  New Uses for Old Drugs in HIV Infection , 2012, Drugs.

[28]  Brian K. Shoichet,et al.  ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..

[29]  B. Palsson,et al.  The model organism as a system: integrating 'omics' data sets , 2006, Nature Reviews Molecular Cell Biology.

[30]  Thomas C. Wiegers,et al.  The Comparative Toxicogenomics Database: update 2013 , 2012, Nucleic Acids Res..

[31]  A. Sandler,et al.  Inhibition of angiogenesis in the treatment of non‐small cell lung cancer , 2007, Cancer science.

[32]  C. Pepine,et al.  Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease , 2004, The American journal of cardiology.

[33]  K. Bretonnel Cohen,et al.  Text mining for the biocuration workflow , 2012, Database J. Biol. Databases Curation.

[34]  K. Durongpisitkul,et al.  The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. , 1995, Pediatrics.

[35]  P. Hillemanns,et al.  A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  Alfonso Valencia,et al.  How to link ontologies and protein–protein interactions to literature: text-mining approaches and the BioCreative experience , 2012, Database J. Biol. Databases Curation.

[37]  A. Barabasi,et al.  Network biology: understanding the cell's functional organization , 2004, Nature Reviews Genetics.

[38]  Xin Wen,et al.  BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities , 2006, Nucleic Acids Res..

[39]  A. Casini,et al.  New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: Mechanistic and pharmacological implications , 2008, FEBS letters.

[40]  Gergely Zahoránszky-Köhalmi,et al.  Drug Effect Prediction by Polypharmacology-Based Interaction Profiling , 2012, J. Chem. Inf. Model..

[41]  Shuxing Zhang,et al.  Mapping drug-target interaction networks , 2009, 2009 Annual International Conference of the IEEE Engineering in Medicine and Biology Society.

[42]  Thomas C. Wiegers,et al.  The Comparative Toxicogenomics Database: update 2011 , 2010, Nucleic Acids Res..

[43]  Deok-Sun Lee,et al.  A Mapping of Drug Space from the Viewpoint of Small Molecule Metabolism , 2009, PLoS Comput. Biol..

[44]  Malorye Allison,et al.  NCATS launches drug repurposing program , 2012, Nature Biotechnology.

[45]  A. Hopkins.  Network pharmacology , 2007, Nature Biotechnology.

[46]  Pekka Tiikkainen,et al.  Computational tools for polypharmacology and repurposing. , 2011, Future medicinal chemistry.

[47]  K. Shokat,et al.  Targeted polypharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases , 2008, Nature chemical biology.

[48]  Meir Glick,et al.  Prediction of Biological Targets for Compounds Using Multiple-Category Bayesian Models Trained on Chemogenomics Databases , 2006, J. Chem. Inf. Model..

[49]  Richard D. Smith,et al.  Binding MOAD, a high-quality protein–ligand database , 2007, Nucleic Acids Res..

[50]  Michael J. Keiser,et al.  Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.

[51]  R. Iyengar,et al.  Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. , 2012, Annual review of pharmacology and toxicology.

[52]  Sarah L. Kinnings,et al.  Novel computational approaches to polypharmacology as a means to define responses to individual drugs. , 2012, Annual review of pharmacology and toxicology.

[53]  C. Supuran,et al.  Polypharmacology of sulfonamides: pazopanib, a multitargeted receptor tyrosine kinase inhibitor in clinical use, potently inhibits several mammalian carbonic anhydrases. , 2012, Chemical communications.

[54]  Tudor I. Oprea,et al.  Cross-pharmacology analysis of G protein-coupled receptors. , 2011, Current topics in medicinal chemistry.

[55]  J. DiMasi,et al.  Risks in new drug development: Approval success rates for investigational drugs , 2001, Clinical pharmacology and therapeutics.

[56]  D. Amory,et al.  Dosing frequency of aspirin and prevention of heart attacks and strokes. , 2007, The American journal of medicine.

[57]  Tudor I. Oprea,et al.  WOMBAT: World of Molecular Bioactivity , 2005 .

[58]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[59]  Joanna L. Sharman,et al.  IUPHAR-DB: new receptors and tools for easy searching and visualization of pharmacological data , 2010, Nucleic Acids Res..

[60]  Tudor I. Oprea,et al.  Drug Repurposing: Far Beyond New Targets for Old Drugs , 2012, The AAPS Journal.

[61]  Christian von Mering,et al.  STITCH: interaction networks of chemicals and proteins , 2007, Nucleic Acids Res..

[62]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[63]  Philip E. Bourne,et al.  A Multidimensional Strategy to Detect Polypharmacological Targets in the Absence of Structural and Sequence Homology , 2010, PLoS Comput. Biol..

[64]  Philip E. Bourne,et al.  SuperTarget goes quantitative: update on drug–target interactions , 2011, Nucleic Acids Res..

[65]  J. Baron.  Aspirin and cancer: trials and observational studies. , 2012, Journal of the National Cancer Institute.

[66]  J. Alpert,et al.  Therapy of symptomatic pericarditis after myocardial infarction: retrospective and prospective studies of aspirin, indomethacin, prednisone, and spontaneous resolution. , 1981, American heart journal.

[67]  P. Bork,et al.  Drug Target Identification Using Side-Effect Similarity , 2008, Science.

[68]  Susumu Goto,et al.  KEGG for integration and interpretation of large-scale molecular data sets , 2011, Nucleic Acids Res..

[69]  B. Martín-Castillo,et al.  Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions. , 2011, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[70]  A. Sands,et al.  Knockouts model the 100 best-selling drugs—will they model the next 100? , 2003, Nature Reviews Drug Discovery.

[71]  J. Irwin,et al.  Docking and chemoinformatic screens for new ligands and targets. , 2009, Current opinion in biotechnology.

[72]  G. V. Paolini,et al.  Global mapping of pharmacological space , 2006, Nature Biotechnology.

[73]  Andreas Schmid,et al.  Systems biology: Hypothesis-driven omics integration. , 2010, Nature chemical biology.

[74]  Xiaoqin Zou,et al.  An inverse docking approach for identifying new potential anti-cancer targets. , 2011, Journal of molecular graphics & modelling.

[75]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[76]  C. Chong,et al.  New uses for old drugs , 2007, Nature.

[77]  Zukang Feng,et al.  Ligand Depot: a data warehouse for ligands bound to macromolecules , 2004, Bioinform..

[78]  Yadi Zhou,et al.  Prediction of Chemical-Protein Interactions Network with Weighted Network-Based Inference Method , 2012, PloS one.

[79]  John Kenneth Morrow,et al.  Molecular networks in drug discovery. , 2010, Critical reviews in biomedical engineering.

[80]  R. Iyengar,et al.  Systems approaches to polypharmacology and drug discovery. , 2010, Current opinion in drug discovery & development.

[81]  Judith A. Blake,et al.  Integrating text mining into the MGI biocuration workflow , 2009, Database J. Biol. Databases Curation.